Mission BioCapital and 4BIO Capital led $28m Series A round in March Biosciences.

Mission BioCapital, a venture capital company, and 4BIO Capital, an venture capital firm, led $28m Series A round in March Biosciences, a clinical stage biotechnology company. “For far too long, T-cell cancers have been an innovation desert with patients facing a dismal prognosis. March Bio’s innovative autologous CAR-T approach brings patients new hope. MB-105 is specifically engineered for relapsed and refractory CD5 positive T-cell lymphomas and I am delighted that this targeted approach combined with the incredible team led by Sarah is moving rapidly into Phase 2 to bring this exciting new treatment to patients. We are honored to be a co-lead investor in March Bio and to help support the company as it continues in its mission to bring transformative therapies to those in urgent need," Owen Smith, 4BIO Capital Partner.